ImmunityBio Shares Rise as Investors Revisit ANKTIVA Expansion and Revenue Momentum

ImmunityBio (IBRX) is up 11.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a mix of renewed optimism around ANKTIVA’s international expansion, solid recent commercial growth, and momentum buying in a stock with notably heavy short interest. There does not appear to be a fresh company press release today, so part of the rally could also be technical and sentiment-driven.

Details:

ImmunityBio’s most recent quarterly update showed record second-quarter 2026 net product revenue of $50.7 million, up 92% year over year, with first-half revenue reaching $94.8 million.

The company said in May that the FDA accepted its supplemental BLA for ANKTIVA plus BCG in papillary bladder cancer, with a PDUFA date of January 6, 2027, giving investors a visible regulatory catalyst ahead.

In late July, ImmunityBio announced a broad UAE authorization for ANKTIVA in bladder and lung cancer, extending the drug’s international footprint and reinforcing the company’s commercial expansion story.

This could also be because the stock remains heavily shorted, which can amplify upside when buyers return and sentiment improves.

Sources:

ImmunityBio, SEC, MarketBeat

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$IBRX Insider Trading Activity

$IBRX insiders have traded $IBRX stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.

Here’s a breakdown of recent trading of $IBRX stock by insiders over the last 6 months:

CHRISTOBEL SELECKY has made 0 purchases and 3 sales selling 256,200 shares for an estimated $2,310,281.
CHERYL COHEN sold 131,210 shares for an estimated $1,246,941
BARRY J. SIMON has made 0 purchases and 2 sales selling 48,033 shares for an estimated $362,213.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$IBRX Hedge Fund Activity

We have seen 194 institutional investors add shares of $IBRX stock to their portfolio, and 137 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

D. E. SHAW & CO., INC. added 11,551,019 shares (+inf%) to their portfolio in Q2 2026, for an estimated $101,129,171
BLACKROCK, INC. added 7,736,819 shares (+29.4%) to their portfolio in Q2 2026, for an estimated $67,735,850
TWO SIGMA INVESTMENTS, LP added 6,711,606 shares (+153.0%) to their portfolio in Q2 2026, for an estimated $58,760,110
MILLENNIUM MANAGEMENT LLC added 4,159,549 shares (+292.9%) to their portfolio in Q2 2026, for an estimated $36,416,851
HRT FINANCIAL LP removed 3,925,446 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $34,367,279
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 2,888,607 shares (+inf%) to their portfolio in Q2 2026, for an estimated $25,289,754
TANG CAPITAL MANAGEMENT LLC removed 2,333,333 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $20,428,330

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$IBRX Analyst Ratings

Wall Street analysts have issued reports on $IBRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 05/21/2026

To track analyst ratings and price targets for $IBRX, check out Quiver Quantitative's $IBRX forecast page.

$IBRX Price Targets

Multiple analysts have issued price targets for $IBRX recently. We have seen 3 analysts offer price targets for $IBRX in the last 6 months, with a median target of $15.0.

Here are some recent targets:

Andres Y. Maldonado from HC Wainwright & Co. set a target price of $15.0 on 06/02/2026
Jeet Mukherjee from BTIG set a target price of $12.0 on 05/21/2026
Jason Kolbert from D. Boral Capital set a target price of $23.0 on 05/05/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.